- Home
- PRTA vs AUTL Comparison
PRTA vs AUTL Comparison
Compare PRTA & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRTA | AUTL |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | Ireland | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 495.8M | 433.8M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | PRTA | AUTL |
|---|---|---|
| Price | $9.12 | $1.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 3 |
| Target Price | ★ $18.86 | $8.67 |
| AVG Volume (30 Days) | 729.9K | ★ 2.5M |
| Earning Date | 02-19-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $11,786,000.00 | ★ $51,128,000.00 |
| Revenue This Year | N/A | $669.49 |
| Revenue Next Year | $819.08 | $91.53 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 406.67 |
| 52 Week Low | $4.32 | $1.11 |
| 52 Week High | $16.67 | $2.70 |
Technical Indicators
Market Signals| Indicator | PRTA | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 41.47 | 55.54 |
| Support Level | $8.95 | $1.77 |
| Resistance Level | $9.47 | $2.07 |
| Average True Range (ATR) | 0.37 | 0.13 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 25.63 | 48.68 |
Price Performance
Historical ComparisonAbout PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.